{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:48:24Z","timestamp":1768009704642,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2002<\/jats:title>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>The aim of this study was to compare antithrombotic regimens after transcatheter aortic valve implantation (TAVI) in patients without an indication for long-term anticoagulation. TAVI is a safe and effective approach for patients with symptomatic severe aortic stenosis and an intermediate-to-high surgical risk. Nevertheless, the antithrombotic regimen after procedure remains controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We systematically searched PubMed, Embase and Cochrane databases for interventional studies comparing single antiplatelet therapy with double antiplatelet therapy after TAVI. A meta-analysis was carried out to compare thrombotic and bleeding events between both strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Four randomized clinical trials were included comprising a total of 1085 patients. Our meta-analysis revealed a higher odds ratio (OR) of major bleeding events (pooled OR 2.45, 95% confidence interval (CI) 1.29\u20134.67; P &amp;lt; 0.01; I2 = 0%) and minor bleeding (pooled OR 1.73, 95% CI 1.12\u20132.66; P = 0.01; I2 = 0%) for the double antiplatelet therapy group compared with the single antiplatelet therapy group. There was no difference between groups in the risk of stroke (pooled OR 1.04, 95% CI 0.58\u20131.86; P = 0.91; I2 = 0%), myocardial infarction (pooled OR 2.10, 95% CI 0.75\u20135.84; P = 0.16, I2 = 0%) and all-cause mortality (pooled OR 1.07, 95% CI 0.63\u20131.86; P = 0.08; I2 = 0%) after TAVI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Our pooled analysis suggests that for patients who underwent TAVI, double antiplatelet therapy compared with single antiplatelet therapy alone increased the risk of bleeding without reducing mortality and ischaemic events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezab250","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T19:20:27Z","timestamp":1619464827000},"page":"1022-1029","source":"Crossref","is-referenced-by-count":2,"title":["Antiplatelet therapy after transcatheter aortic valve implantation: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-3690","authenticated-orcid":false,"given":"Gon\u00e7aloNuno Ferraz","family":"Costa","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Costa","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lino","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal"},{"name":"Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-2247","authenticated-orcid":false,"given":"Rog\u00e9rio","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal"},{"name":"Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"2021110219162051300_ezab250-B1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"2021110219162051300_ezab250-B2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis","volume":"370","author":"Adams","year":"2014","journal-title":"N Engl J Med"},{"key":"2021110219162051300_ezab250-B3","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","volume":"380","author":"Popma","year":"2019","journal-title":"N Engl J Med"},{"key":"2021110219162051300_ezab250-B4","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jcin.2018.07.032","article-title":"1-Year outcomes with the Evolut R self-expanding transcatheter aortic valve: from the international FORWARD study","volume":"11","author":"Manoharan","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2021110219162051300_ezab250-B5","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/eurheartj\/ehx294","article-title":"SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve","volume":"38","author":"Wendler","year":"2017","journal-title":"Eur Heart J"},{"key":"2021110219162051300_ezab250-B6","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2021110219162051300_ezab250-B7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet"},{"key":"2021110219162051300_ezab250-B8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jtcvs.2012.09.002","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document","volume":"145","author":"Kappetein","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021110219162051300_ezab250-B9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110219162051300_ezab250-B10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"2021110219162051300_ezab250-B11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"Int J Cardiol"},{"key":"2021110219162051300_ezab250-B12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2021110219162051300_ezab250-B13","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","article-title":"Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE)","volume":"24","author":"Moscucci","year":"2003","journal-title":"Eur Heart J"},{"key":"2021110219162051300_ezab250-B14","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.jacc.2019.08.1032","article-title":"Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review topic of the week","volume":"74","author":"Mangieri","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021110219162051300_ezab250-B15","first-page":"22","volume-title":"Pharmacol Res","author":"Habib","year":"2015"},{"key":"2021110219162051300_ezab250-B16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2021110219162051300_ezab250-B17","doi-asserted-by":"crossref","first-page":"e1392","DOI":"10.4244\/EIJ-D-17-00198","article-title":"Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI","volume":"13","author":"D'Ascenzo","year":"2017","journal-title":"EuroIntervention"},{"key":"2021110219162051300_ezab250-B18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2018.06.006","article-title":"Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: insights from the STS\/ACC TVT Registry","volume":"204","author":"Sherwood","year":"2018","journal-title":"Am Heart J"},{"key":"2021110219162051300_ezab250-B19","first-page":"95","volume-title":"J Geriatr Cardiol","author":"Davlouros","year":"2018"},{"key":"2021110219162051300_ezab250-B20","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/CIRCULATIONAHA.112.001091","article-title":"Histopathology of embolic debris captured during transcatheter aortic valve replacement","volume":"127","author":"Van Mieghem","year":"2013","journal-title":"Circulation"},{"key":"2021110219162051300_ezab250-B21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jacc.2016.12.002","article-title":"Cerebral embolic protection during TAVR: a clinical event meta-analysis","volume":"69","author":"Giustino","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021110219162051300_ezab250-B22","doi-asserted-by":"crossref","first-page":"e003551","DOI":"10.1161\/CIRCINTERVENTIONS.115.003551","article-title":"Neurological events following transcatheter aortic valve replacement and their predictors: a report from the CoreValve trials","volume":"9","author":"Kleiman","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"2021110219162051300_ezab250-B23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jacc.2016.05.065","article-title":"Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement","volume":"68","author":"Auffret","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021110219162051300_ezab250-B24","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.4244\/EIJ-D-16-00558","article-title":"Post-procedural myocardial infarction following surgical aortic valve replacement and transcatheter aortic valve implantation","volume":"13","author":"Dobson","year":"2017","journal-title":"EuroIntervention"},{"key":"2021110219162051300_ezab250-B25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.athoracsur.2009.12.033","article-title":"Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation","volume":"89","author":"Dewey","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"2021110219162051300_ezab250-B26","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"2021110219162051300_ezab250-B27","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2021110219162051300_ezab250-B28","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"key":"2021110219162051300_ezab250-B29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement","volume":"382","author":"De Backer","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110219162051300_ezab250-B30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ejcts\/article-pdf\/60\/5\/1022\/41055253\/ezab250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ejcts\/article-pdf\/60\/5\/1022\/41055253\/ezab250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T21:48:07Z","timestamp":1635889687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/60\/5\/1022\/6306824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,1,20]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezab250","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"value":"1010-7940","type":"print"},{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,1,20]]}}}